Trial Condition(s):

Hypertension, Pulmonary, Ventricular Dysfunction, Left

Hemodynamic and echocardiographic assessment of Riociguat effects on myocardial wall contractility and relaxation kinetics (HEARTWORK)

Bayer Identifier:

14549

ClinicalTrials.gov Identifier:

NCT01065051

EudraCT Number:

Not Available

Terminated/Withdrawn

Trial Purpose

The aim of this study is to assess whether oral Riociguat affects the left ventricular contractility and relaxation in patients with pulmonary hypertension associated with left ventricular systolic dysfunction

Inclusion Criteria
- Male and female patients with symptomatic pulmonary hypertension due to left ventricular systolic dysfunction despite standard heart failure therapy
Exclusion Criteria
- Types of pulmonary hypertension other than group 2.1 of Dana Point Classification

Trial Summary

Enrollment Goal
1
Trial Dates
black-arrow
Phase
2
Could I receive a placebo?
Yes
Products
Adempas (Riociguat, BAY63-2521)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Massachusetts General Hospital

Boston, United States, 02114-2696

Status
Completed
 
Locations

Mayo Clinic - Rochester

Rochester, United States, 55905

Status
Terminated
 

Trial Design